Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
AZD3480 versus donepezil and placebo in Alzheimer's disease
2007-000835-24Phase 2Completed
- Sponsor
- AstraZeneca
- Start
- May 2007
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of ispronicline in Alzheimer's disease (AD) (3 arms), sponsored by AstraZeneca. Primary endpoint: Change from baseline in ADAS-Cog at week 12. Started May 2007; status: completed.
02
Drugs
ispronicline
03
Conditions
Alzheimer's disease (AD)
Beyond the preview
Go deeper on 2007-000835-24.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2007-000835-24.